Mitosis-targeted anti-cancer therapies: Where they stand

Cell Death and Disease

Volumn 3, Issue 10, 2012, Pages

  Chan, K S ^a   Koh, C G ^a   Li, H Y ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antimitotic; Cancer; Chemotherapy; Mitotic slippage; Tumor growth

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; 7 HYDROXYSTAUROSPORINE; ALISERTIB; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ARRY 520; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AZD 4877; BARASERTIB; BETA TUBULIN; BORTEZOMIB; CELL CYCLE PROTEIN 20; CEP 3891; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHIR 124; CYCLIN DEPENDENT KINASE 1; DANUSERTIB; DELANZOMIB; ENMD 2076; EPOTHILONE DERIVATIVE; FLAVOPIRIDOL; GSK 461364; GSK 923295; ISPINESIB; IXAZOMIB CITRATE; LITRONESIB; MK 0731; MONASTROL; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OPROZOMIB; ORANTINIB; PACLITAXEL; PF 00477736; POLO LIKE KINASE 1; PROTEASOME; RIGOSERTIB; SB 743921; TAK 960; TANESPIMYCIN; TAXANE DERIVATIVE; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VOLASERTIB; XL 844;

BINDING AFFINITY; BREAST CANCER; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; COLON CARCINOMA; DRUG EFFICACY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTERPHASE; KAPOSI SARCOMA; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS; MULTIPLE MYELOMA; NEPHROBLASTOMA; NERVE FIBER TRANSPORT; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW; TESTIS CANCER;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; ENZYME INHIBITORS; HUMANS; MITOSIS; MOLECULAR MOTOR PROTEINS; MULTIPROTEIN COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84870527677     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.148     Document Type: Review

References (139)

1. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
2. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-651.
3. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825-2837.
4. Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? Curr Opin Chem Biol 1999; 3: 77-83.
5. Xi G, Hu X, Wu B, Jiang H, Young CY, Pang Y et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett 2011; 307: 141-148.
6. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003; 5: 309-325.
7. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005; 8: 7-12.
8. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
9. Rowinsky EK, Donehower RC. Paclitaxel (taxol). New Engl J Med 1995; 332: 1004-1014.
10. Pinsky BA, Biggins S. The spindle checkpoint: tension versus attachment. Trends Cell Biol 2005; 15: 486-493.
11. Schmidt M, Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist Update 2007; 10: 162-181.
12. John PC, Mews M, Moore R. Cyclin/Cdk complexes: their involvement in cell cycle progression and mitotic division. Protoplasma 2001; 216: 119-142.
13. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2: 21-32.
14. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783.
15. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006; 21: 3-9.
16. Anderson HJ, Andersen RJ, Roberge M. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. Prog Cell Cycle Res 2003; 5: 423-430.
17. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401: 616-620.
18. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117.
19. Brown JR, Koretke KK, Birkeland ML, Sanseau P, Patrick DR. Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anticancer drugs. BMC Evol Biol 2004; 4: 39.
20. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
21. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5: 429-440.
22. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-854.
23. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10: 825-841.
24. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006; 119: 3664-3675.
25. Kelly AE, Funabiki H. Correcting aberrant kinetochore microtubule attachments: an Aurora B-centric view. Curr Opin Cell Biol 2009; 21: 51-58.
26. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286: 971-974.
27. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000; 150: 975-988.
28. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 2005; 280: 11569-11577.
29. Huszar D, Theoclitou ME, Skolnik J, Herbst R. Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 2009; 28: 197-208.
30. Wood KW, Sakowicz R, Goldstein LS, Cleveland DW. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment. Cell 1997; 91: 357-366.
31. Yao X, Abrieu A, Zheng Y, Sullivan KF, Cleveland DW. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nat Cell Biol 2000; 2: 484-491.
32. Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 107: 5839-5844.
33. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A et al. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007; 6: 1317-1328.
34. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007; 11: 25-36.
35. Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM et al. First-time-inhuman study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 69: 733-741.
36. Thornton BR, Toczyski DP. Securin and B-cyclin/CDK are the only essential targets of the APC. Nat Cell Biol 2003; 5: 1090-1094.
37. Smolders L, Teodoro JG. Targeting the anaphase promoting complex: common pathways for viral infection and cancer therapy. Expert Opin Ther Targets 15: 767-780.
38. Gascoigne KE, Taylor SS. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-122.
39. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009; 16: 347-358.
40. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell 2010; 18: 641-654.
41. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010; 18: 382-395.
42. Ciechanover A, Schwartz AL. The ubiquitin system: pathogenesis of human diseases and drug targeting. BBA - Mol Cell Res 2004; 1695: 3-17.
43. Einsele H. Bortezomib. Recent Results Cancer Res 2010; 184: 173-187.
44. Shen L, Au WY, Wong KY, Shimizu N, Tsuchiyama J, Kwong YL et al. Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells. Mol Cancer Ther 2008; 7: 3807-3815.
45. Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. Oncol Rep 2008; 19: 1027-1032.
46. Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H et al. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2008; 134: 323-330.
47. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A et al. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumors. Eur J Cancer 2008; 44: 1829-1834.
48. Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer 2010; 116: 3463-3468.
49. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16: 444-454.
50. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated byMCL1 and FBW7. Nature 2011; 471: 110-114.
51. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000.
52. Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2003; 199: 90-97.
53. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2011; 11: 141-150.
54. Dalton WB, Nandan MO, Moore RT, Yang VW. Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res 2007; 67: 11487-11492.
55. Lai SK, Wong CH, Lee YP, Li HY. Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death. Cell Death Differ 2011; 18: 996-1004.
56. Ono T, Fang Y, Spector DL, Hirano T. Spatial and temporal regulation of Condensins I and II in mitotic chromosome assembly in human cells. Mol Biol Cell 2004; 15: 3296-3308.
57. Zhai L, Wang H, Tang W, Liu W, Hao S, Zeng X. Disturbance in function and expression of condensin affects chromosome compaction in HeLa cells. Cell Biol Int 2011; 35: 735-740.
58. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012; 18: 51-63.
59. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322.
60. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997; 43: 7-14.
61. Szende B, Romics I, Minik K, Szabo J, Torda I, Lovasz S et al. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma. Prostate 2001; 49: 93-100.
62. Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994; 25: 337-342.
63. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012; 23: 1-6.
64. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17: 3420-3430.
65. Souid AK, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM et al. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010; 55: 1323-1328.
66. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 2006; 58: 665-672.
67. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292.
68. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
69. Tcherniuk S, van Lis R, Kozielski F, Skoufias DA. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines. Biochem Pharmacol 2010; 79: 864-872.
70. Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997; 57: 1597-1604.
71. McClelland SE, Burrell RA, Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 2009; 8: 3262-3266.
72. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 2004; 101: 8699-8704.
73. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 2010; 70: 10255-10264.
74. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci USA 2009; 106: 19108-19113.
75. Mazzorana M, Montoya G, Mortuza GB. The centrosome: a target for cancer therapy. Curr Cancer Drug Targets 2011; 11: 600-612.
76. Smith P, Syed N, Crook T. Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3. Cell Cycle 2006; 5: 1262-1264.
77. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005; 37: 883-888.
78. Blundell TL, Sibanda BL, Montalvao RW, Brewerton S, Chelliah V, Worth CL et al. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond B Biol Sci 2006; 361: 413-423.
79. Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006; 18: 616-622.
80. Dohi T, Okada K, Xia F,Wilford CE, Samuel T, Welsh K et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-34090.
81. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007; 27: 17-28.
82. Chan KS, Wong CH, Huang YF, Li HY. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 2010; 1: e57.
83. Wong CH, Chan H, Ho CY, Lai SK, Chan KS, Koh CG et al. Apoptotic histone modification inhibits nuclear transport by regulating RCC1. Nat Cell Biol 2009; 11: 36-45.
84. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60: 2805-2809.
85. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S, Shafit-Zagardo B. Survivin inhibition induces human neural tumor cell death through caspase-independent anddependent pathways. J Neurochem 2001; 79: 426-436.
86. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003; 14: 3325-3341.
87. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S et al. Pleiotropic celldivision defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1: 461-466.
88. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012; 14: 120-128.
89. Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, Ferlini C. Novel drugs targeting microtubules: the role of epothilones. Curr Pharm Design 2012; 18: 2793-2803.
90. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007; 13: 591-602.
91. Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res 2004; 64: 9035-9040.
92. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007; 6: 104-110.
93. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P et al. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat 2012; 131: 933-937.
94. Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G et al. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol 2012; 124: 210-215.
95. Jackman KM, Frye CB, Hunger SP. Flavopiridol displays preclinical activity in acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50: 772-778.
96. Li Y, Tanaka K, Li X, Okada T, Nakamura T, Takasaki M et al. Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells. Int J Cancer 2007; 121: 1212-1218.
97. Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 2008; 14: 523-532.
98. Kummar S, Gutierrez ME, Gardner ER, Figg WD, Melillo G, Dancey J et al. A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 2010; 65: 383-389.
99. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T et al. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs 30: 741-748.
100. Lin JP, Yang JS, Lee JH, Hsieh WT, Chung JG. Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line. World J Gastroenterol 2006; 12: 21-28.
101. Choi EJ, Kim GH. Daidzein causes cell cycle arrest at the G1 and G2/M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine 2008; 15: 683-690.
102. Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatinresistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther 2007; 6: 926-934.
103. Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009; 23: 961-970.
104. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W. Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer 2009; 8: 8.
105. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008; 93: 662-669.
106. Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L et al. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006; 12: 4080-4089.
107. Ellis PM, Chu QS, Leighl N, Laurie SA, Fritsch H, Gaschler-Markefski B et al. A phase i open-label dose-escalation study of intravenous bi 2536 together with Pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 2012; e-pub ahead of print 31 May 2012; doi:10.1016/j.cllc. 2012.04.003.
108. Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM et al. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012; 107: 280-286.
109. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008; 26: 5504-5510.
110. Schoffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P et al. A phase I, doseescalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48: 179-186.
111. Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S et al. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 2012; 11: 700-709.
112. Gomez HL, Philco M, Pimentel P, Kiyan M, Monsalvo ML, Conlan MG et al. Phase I doseescalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. Anticancer Drugs 2011; 23: 335-341.
113. Burris HA 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011; 29: 467-472.
114. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J et al. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemoth Pharm 2012; 69: 165-172.
115. Theoclitou ME, Aquila B, Block MH, Brassil PJ, Castriotta L, Code E et al. Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2] thiazolo[5,4-d]pyrimidin -6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. J Med Chem 2011; 54: 6734-6750.
116. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010; 116: 4906-4915.
117. Mato AR, Feldman T, Goy A. Proteasome inhibition and combination therapy for Non-Hodgkin's lymphoma: from bench to bedside. Oncologist 2012; 17: 694-707.
118. Benga G. Basic studies on gene therapy of human malignant melanoma by use of the human interferon beta gene entrapped in cationic multilamellar liposomes. 1. Morphology and growth rate of six melanoma cell lines used in transfection experiments with the human interferon beta gene. J Cell Mol Med 2001; 5: 402-408.
119. Cendan JC, Souba WW, Copeland EM 3rd, Lind DS. Increased L-arginine transport in a nitric oxide-producing metastatic colon cancer cell line. Ann Surg Oncol 1996; 3: 501-508.
120. Gonzalez-Moreno O, Calvo A, Joshi BH, Abasolo I, Leland P, Wang Z et al. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int J Cancer 2005; 114: 870-878.
121. Hayostek CJ, Koval TM. Radiosensitization of human tumor cells with levamisole. Cancer Res 1992; 52: 3228-3230.
122. Kim EH, Lee HJ, Lee DH, Bae S, Soh JW, Jeoung D et al. Inhibition of heat shock protein 27-mediated resistance to DNA damaging agents by a novel PKC delta-V5 heptapeptide. Cancer Res 2007; 67: 6333-6341.
123. Ku JL, Kim KH, Choi JS, Jeon YK, Kim SH, Shin YK et al. Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes. Cell Oncol 2011; 34: 45-54.
124. Li G, Nelsen C, Hendrickson EA. Ku86 is essential in human somatic cells. Proc Natl Acad Sci USA 2002; 99: 832-837.
125. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998; 273: 5939-5947.
126. Sharma M, Dube A, Bansal H, Kumar Gupta P. Effect of pH on uptake and photodynamic action of chlorin p6 on human colon and breast adenocarcinoma cell lines. Photochem Photobiol Sci 2004; 3: 231-235.
127. Watanabe N, Okochi E, Mochizuki M, Sugimura T, Ushijima T. The presence of single nucleotide instability in human breast cancer cell lines. Cancer Res 2001; 61: 7739-7742.
128. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD. RNA interferencemediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 2004; 64: 3137-3143.
129. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K et al. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996; 10: 130-137.
130. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999; 23: 127-136.
131. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712-2716.
132. Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 1980; 56: 344-350.
133. Hagenbeek A, Martens AC. Detection of minimal residual disease in acute leukemia: possibilities and limitations. Eur J Cancer Clin Oncol 1985; 21: 389-395.
134. Raza A, Preisler HD, Day R, Yasin Z, White M, Lykins J et al. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood 1990; 76: 2191-2197.
135. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.
136. Trere D, Pession A, Basso G, Rondelli R, Masera G, Paolucci G et al. Prognostic relevance of pretreatment proliferative rapidity of marrow blast cells in childhood acute lymphoblastic leukaemia. Br J Cancer 1994; 70: 1198-1202.
137. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-1464.
138. Okabe S, Tauchi T, Ohyashiki K. Establishment of a new Philadelphia chromosomepositive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation. Exp Hematol 2010; 38: 765-772.
139. Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 19: 435-441.